Equities Analysts Set Expectations for BMY FY2025 Earnings

Bristol-Myers Squibb (NYSE:BMY) – Equities research analysts at Cantor Fitzgerald upped their FY2025 EPS estimates for shares of Bristol-Myers Squibb in a note issued to investors on Wednesday, April 30th. Cantor Fitzgerald analyst C. Gould now forecasts that the biopharmaceutical company will earn $6.89 per share for the year, up from their previous estimate of $6.81. Cantor Fitzgerald has a “Neutral” rating and a $55.00 price objective on the stock. The consensus estimate for Bristol-Myers Squibb’s current full-year earnings is $6.74 per share.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analysts’ expectations of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Bristol-Myers Squibb’s revenue was down 5.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($4.40) EPS.

A number of other research analysts also recently issued reports on the company. UBS Group cut their price objective on Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a research note on Friday, April 11th. Piper Sandler assumed coverage on Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 price target for the company. Wells Fargo & Company upped their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a research report on Friday, February 7th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Finally, William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $58.00.

Bristol-Myers Squibb Stock Up 2.0 %

Bristol-Myers Squibb stock opened at $50.21 on Thursday. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The stock has a market cap of $102.18 billion, a PE ratio of -11.36, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41. The stock has a fifty day moving average of $55.99 and a 200 day moving average of $56.41. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be paid a $0.62 dividend. The ex-dividend date is Friday, April 4th. This represents a $2.48 annualized dividend and a yield of 4.94%. Bristol-Myers Squibb’s payout ratio is currently 92.88%.

Insider Activity

In other news, EVP Samit Hirawat acquired 4,250 shares of the business’s stock in a transaction on Friday, April 25th. The shares were purchased at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the acquisition, the executive vice president now directly owns 83,513 shares of the company’s stock, valued at $3,973,548.54. This represents a 5.36 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.09% of the company’s stock.

Institutional Trading of Bristol-Myers Squibb

Several hedge funds and other institutional investors have recently bought and sold shares of BMY. Pinney & Scofield Inc. acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at $25,000. Park Square Financial Group LLC acquired a new stake in Bristol-Myers Squibb during the fourth quarter valued at approximately $26,000. Global Wealth Strategies & Associates grew its holdings in shares of Bristol-Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 275 shares during the last quarter. Transce3nd LLC purchased a new stake in Bristol-Myers Squibb during the fourth quarter valued at about $28,000. Finally, Fairway Wealth LLC purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $28,000. 76.41% of the stock is owned by institutional investors.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.